Development
ImmunoPrecise Antibodies Ltd.
IPA
$0.6724
-$0.0296-4.22%
NASDAQ
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 4.33M | 5.12M | 6.11M | 8.49M | 11.04M |
| Total Receivables | 3.64M | 3.75M | 3.26M | 2.45M | 3.29M |
| Inventory | 1.77M | 1.68M | 1.52M | 1.36M | 1.16M |
| Prepaid Expenses | 1.36M | 1.41M | 1.50M | 1.86M | 1.14M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 11.09M | 11.95M | 12.38M | 14.15M | 16.63M |
|
|
|||||
| Total Current Assets | 11.09M | 11.95M | 12.38M | 14.15M | 16.63M |
| Net Property, Plant & Equipment | 8.54M | 9.37M | 7.66M | 7.85M | 7.04M |
| Long-term Investments | 13.62M | 14.24M | 14.14M | 15.83M | 14.41M |
| Goodwill | 13.62M | 14.24M | 14.14M | 15.83M | 14.41M |
| Total Other Intangibles | 20.84M | 22.32M | 22.79M | 23.60M | 22.20M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 343.40K | 322.30K | 322.20K | 321.70K | 332.90K |
| Total Assets | 54.44M | 58.22M | 57.38M | 61.81M | 60.68M |
|
|
|||||
| Total Accounts Payable | 1.95M | 1.79M | 1.83M | 2.70M | 3.16M |
| Total Accrued Expenses | 1.01M | 933.50K | 665.10K | 524.90K | 389.40K |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 686.90K | 792.10K | 822.90K | 968.00K | 847.00K |
| Total Finance Division Other Current Liabilities | 1.78M | 1.36M | 1.04M | 793.30K | 957.70K |
| Total Other Current Liabilities | 1.78M | 1.36M | 1.04M | 793.30K | 957.70K |
| Total Current Liabilities | 5.42M | 4.88M | 4.37M | 4.99M | 5.36M |
|
|
|||||
| Total Current Liabilities | 5.42M | 4.88M | 4.37M | 4.99M | 5.36M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 6.21M | 6.67M | 4.54M | 4.64M | 4.06M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 5.34M | 5.74M | 5.85M | 6.39M | 6.00M |
| Total Liabilities | 16.97M | 17.29M | 14.76M | 16.01M | 15.41M |
|
|
|||||
| Common Stock & APIC | 93.16M | 98.14M | 94.58M | 95.70M | 93.38M |
| Retained Earnings | -57.08M | -58.27M | -53.90M | -50.96M | -46.39M |
| Treasury Stock & Other | 1.39M | 1.07M | 1.94M | 1.06M | -1.71M |
| Total Common Equity | 37.46M | 40.93M | 42.62M | 45.80M | 45.28M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 37.46M | 40.93M | 42.62M | 45.80M | 45.28M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 37.46M | 40.93M | 42.62M | 45.80M | 45.28M |
|
|
|||||